Cardiovascular disease associated with androgen-deprivation therapy : Time to give it due respect

Journal of Clinical Oncology

Volumn 33, Issue 11, 2015, Pages 1232-1234

  Basaria, Shehzad ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ESTRADIOL; ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; TESTOSTERONE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; EDITORIAL; PRIORITY JOURNAL; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; HUMAN; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; HUMANS; MALE; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 84927144431     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.2649     Document Type: Editorial

References (31)

1. Huggins C, Stevens RE Jr, Hodges CV: Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223, 1941
2. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 65:5-29, 2015
3. Shahani S, Braga-Basaria M, Basaria S: ADT in prostate cancer and metabolic risk for atherosclerosis. J Clin Endocrinol Metab 93:2042-2049, 2008
4. Basaria S: Male hypogonadism. Lancet 383:1250-1263, 2014
5. Bhasin S, Cunningham GR, Hayes FJ, et al: Testosterone therapy in adult men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95:2536-2559, 2010
6. Morote J, Orsola A, Planas J, et al: Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178:1290-1295, 2007
7. Laaksonen DE, Niskanen L, Punnonen K, et al: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041, 2004
8. Hak AE, Witteman JC, de Jong FH, et al: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab 87:3632-3639, 2002
9. Shores MM, Matsumoto AM, Sloan KL, et al: Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660-1665, 2006
10. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93:68-75, 2008
11. Singh R, Artaza JN, Taylor WE, et al: Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 144:5081-5089, 2003
12. Nathan L, Shi W, Dinh H, et al: Testosterone inhibits early atherogenesis by conversion to estradiol: Critical role of aromatase. Proc Natl Acad Sci U S A 98:3589-3593, 2001
13. Smith MR, Goode M, Zietman AL, et al: Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: Effects on bone mineral density and body composition. J Clin Oncol 22:2546-2553, 2004
14. Basaria S: Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: An inconvenient truth. J Androl 29:534-539, 2008
15. Smith JC, Bennett S, Evans LM, et al: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267, 2001
16. Basaria S, Muller DC, Carducci MA, et al: Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106:581-588, 2006
17. Braga-Basaria M, Dobs AS, Muller DC, et al: Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol 24:3979-3983, 2006
18. Keating NL, O'Malley AJ, Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24:4448-4456, 2006
19. Saigal CS, Gore JL, Krupski TL, et al: Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 110: 1493-1500, 2007
20. Tsai HK, D'Amico AV, Sadetsky N, et al: Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 99:1516-1524, 2007
21. Nanda A, Chen MH, Braccioforte MH, et al: Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA 302:866-873, 2009
22. Azoulay L, Yin H, Benayoun S, et al: Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Eur Urol 60:1244-1250, 2011
23. Hu JC, Williams SB, O'Malley AJ, et al: Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol 61:1119-1128, 2012
24. US Food and Drug Administration: FDA drug safety communication: Update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. http://www.fda .gov/Drugs/DrugSafety/ucm229986.htm
25. D'Amico AV, Denham JW, Crook J, et al: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 25:2420-2425, 2007
26. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 27:92-99, 2009
27. Efstathiou JA, Bae K, Shipley WU, et al: Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: Analysis of RTOG 92-02. Eur Urol 54:816-823, 2008
28. Nguyen PL, Je Y, Schutz FA, et al: Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: A metaanalysis of randomized trials. JAMA 306:2359-2366, 2011
29. O'Farrell S, Garmo H, Holmberg L, et al: Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol 33:1243-1251, 2015
30. Jespersen CG, Nørgaard M, Borre M: Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: A nationwide Danish population-based cohort study. Eur Urol 65:704-709, 2014
31. Smith MR, Klotz L, Persson BE, et al: Cardiovascular safety of degarelix: Results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. J Urol 184:2313-2319, 2010